Equity Overview
Price & Market Data
Price: $57.65
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $5,501,376,000
Daily Volume: 0
Performance Metrics
1 Week: 3.78%
1 Month: 37.46%
3 Months: 37.95%
6 Months: 45.54%
1 Year: 88.21%
YTD: 28.63%
Company Details
Employees: 370
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.